CMID Practice Test

Session length

1 / 20

In a patient with a history of breast cancer, which panel would be most valuable to determine the diagnosis of mediastinal lymph node cells?

GATA3 +, Napsin A-

Napsin A +, GATA3 -

GATA 3+, ER/PR/HER2(-/+)

Determining tissue origin for metastatic lymph node cells relies on lineage-specific markers. GATA3 is a strong indicator of breast (and urothelial) origin, while the ER/PR/HER2 receptor status provides breast-specific phenotype information. In contrast, Napsin A and TTF-1 point toward a lung primary if they are positive.

In a patient with a history of breast cancer, a panel that shows GATA3 positivity along with the breast-related receptor profile (ER and/or PR and/or HER2) is the most informative because it directly supports metastatic breast carcinoma and helps distinguish it from a new primary lung cancer. Napsin A or TTF-1 positivity would suggest lung origin, which is less consistent with the history unless proven otherwise.

So, the panel combining GATA3 positivity with ER/PR/HER2 status best identifies metastatic breast cancer in mediastinal lymph node cells.

Napsin A +, TTF-1 +

Next Question

Find the option that is right for you!

All options are one-time payments.

$25.99

30 day premium pass

All the basics to get you started

  • Ad-free experience
  • View your previous attempt history
  • Mobile app access
  • In-depth explanations
  • 30 day premium pass access
👑$59.99 $171.99 usd

6 month DELUXE pass (most popular)

Everything with the 30 day premium pass FOR 6 MONTHS! & the ultimate digital PDF study guide (BONUS)

  • Everything included in the premium pass
  • $171.99 usd value for $59.99! You save $106!
  • + Access to the ultimate digital PDF study guide
  • + 6 months of premium pass access
  • + Priority support
$15.99 $24.99

Ultimate digital PDF study guide

For those that prefer a more traditional form of learning

  • Available for instant download
  • Available offline
  • Hundreds of practice multiple choice questions
  • Comprehensive content
  • Detailed explanations
Image Description
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy